Christina Ackermann - 23 Mar 2023 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Reporting relationship: Director
Issuer ticker: CALC
Reported as of: 23 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Mar 2023, 19:54:44 UTC
Prior SEC filing: 03 Mar 2023
Next SEC filing: 05 Sep 2023
Source filing: View source filing
Reporting owner signature: /s/ Robert S. Breuil, Attorney-in-Fact

Key filing fact

Christina Ackermann filed Form 4 for CalciMedica, Inc. (CALC) on 27 Mar 2023.

Key facts

This page summarizes Christina Ackermann's Form 4 filing for CalciMedica, Inc. (CALC).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 Mar 2023, 19:54.

Change

Previous filing in this sequence was filed on 03 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CALC transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: +1,429
Change %
Price
Shares after: 1,429
Date: 23 Mar 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CALC transaction Derivative

Restricted Stock Unit

Disposed to Issuer

Transaction value
Shares: -1,429
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,429
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christina Ackermann's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.